New Technology– category –
-
BioNTech Announces gotistobart Phase III Achieves Median OS of 18.5 Months in Squamous NSCLC at WCLC 2026
european biotechnology Germany Overview At the World Conference on Lung Cancer (WCLC) 2026 in Seoul, BioNTech presented pivotal data from the Phase III PRESERVE-003 trial for gotistobart (BNT316/ONC-392), a pH-sensitive anti-CTLA-4 antib... -
Novel Bispecific ADC ICP-B381, Targeting PSMA and STEAP1, Approved for Phase 1 Clinical Trials in China for Prostate Cancer; US IND Submission Underway
Prostate Warriors China Overview ICP-B381, a novel bispecific antibody-drug conjugate (ADC) designed to simultaneously target PSMA and STEAP1, has received approval from Chinese regulatory authorities to commence Phase 1 clinical trials ... -
Gan & Lee Pharmaceuticals Initiates Phase I Trial for Once-Weekly Oral GLP-1 Peptide GZC8072 in China, Targeting Obesity and Type 2 Diabetes
AllSci China Overview Gan & Lee Pharmaceuticals Co., Ltd. has commenced its Phase I clinical trial for GZC8072, a novel once-weekly oral GLP-1 receptor peptide agonist, targeting type 2 diabetes and weight management in overweight or...
12